Sign Out
Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma and in the treatment of allergic rhinitis.
Since montelukast is metabolised by CYP3A4, caution should be exercised, particularly in children, when montelukast is co-administered with enzyme inducers of CYP3A4 eg, phenytoin, phenobarbital and rifampicin.
Montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (eg, paclitaxel, rosiglitazone, and repaglinide).
Concurrent use of gemfibrozil and montelukast may result in elevated montelukast plasma concentrations.
Concurrent use of prednisone and montelukast may result in severe peripheral edema.
Concurrent use of montelukast and repaglinide may result in increased repaglinide plasma concentrations.
